---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264594868.md"
description: "AstraZeneca announced its third-quarter results, with total revenue increasing by 12% year-on-year to USD 15.191 billion, and core earnings per share of USD 2.38, exceeding market expectations of USD 2.27, benefiting from strong sales of key cancer and diabetes drugs. Revenue for the first nine months grew by 10% year-on-year to USD 43.236 billion, with core earnings per share of USD 7.04. The company reiterated that full-year revenue will achieve high single-digit growth and core earnings per share will see low double-digit growth, which is broadly in line with market expectations. The company plans to announce a full-year dividend of USD 3.20 per share for 2025, up from USD 3.10 last year"
datetime: "2025-11-06T08:56:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264594868.md)
  - [en](https://longbridge.com/en/news/264594868.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264594868.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264594868.md) | [繁體中文](https://longbridge.com/zh-HK/news/264594868.md)


# 

AstraZeneca announced its third-quarter results, with total revenue increasing by 12% year-on-year to USD 15.191 billion, and core earnings per share of USD 2.38, exceeding market expectations of USD 2.27, benefiting from strong sales of key cancer and diabetes drugs. Revenue for the first nine months grew by 10% year-on-year to USD 43.236 billion, with core earnings per share of USD 7.04. The company reiterated that full-year revenue is expected to achieve high single-digit growth, and core earnings per share are expected to grow in the low double digits, which is broadly in line with market expectations. The company plans to announce a full-year dividend of USD 3.20 per share for 2025, up from USD 3.10 last year

### Related Stocks

- [AstraZeneca PLC (AZN.US)](https://longbridge.com/en/quote/AZN.US.md)
- [AstraZeneca PLC (AZN.UK)](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca says Efzimfotase alfa PH3 program show positive results](https://longbridge.com/en/news/281138062.md)
- [If You Invested $1000 In AstraZeneca Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/281048213.md)
- [AstraZeneca hails positive results in tozorakimab lung disease trials](https://longbridge.com/en/news/280752841.md)
- [AstraZeneca Says Tozorakimab Lowers COPD Exacerbations in Two Late-stage Studies](https://longbridge.com/en/news/280745900.md)
- [J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)](https://longbridge.com/en/news/280821156.md)